Ferronova Pty Ltd. has signed a licensing agreement with the Purdue Research Foundation (PRF) for the application of PRF's fibroblast activation protein (FAP) inhibitor in magnetic resonance imaging (MRI) and MRI-guided therapies.
Xnk Therapeutics AB has entered into a research collaboration with the Karolinska University Hospital to evaluate the suitability of the company's preclinical autologous natural killer (NK) cell therapy candidate XNK-02 as a novel therapy for treatment of acute myeloid leukemia (AML).
Adaptative immune response mediated by NKG2D receptor and its ligand NKG2DL could be the clue for CD8-expressing “killer” T cells to kill tumors lacking the major histocompatibility complex (MHC) class I, according to a group of researchers at Duke University.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors, preferably PARP-1, reported to be useful for the treatment of cancer.
Verismo Therapeutics Inc. has entered into a licensing agreement with the University of Pennsylvania for worldwide exclusive rights for two newly discovered anti-CD19 binders, the result of a sponsored research agreement between the two parties.
Thymidylate synthase (TS) is an enzyme essential for DNA synthesis and cell proliferation and is a potential oncoprotein itself. Consequently, TS is considered a molecular target for malignant tumors.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has described Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer, and autoimmune disease.
Etern Biopharma (Shanghai) Co. Ltd. has divulged transcriptional coactivator YAP1 and TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
